Market Spotlight: Myelodysplastic Syndrome (MDS)

Figure 1: Trends in incident cases of MDS, 2019–28
Figure 2: Overview of pipeline drugs for MDS in the US
Figure 3: Pipeline drugs for MDS, by company
Figure 4: Pipeline drugs for MDS, by drug type
Figure 5: Pipeline drugs for MDS, by classification
Figure 6: Eprenetapopt for MDS (December 28, 2020): Phase III - Frontline (w/Azacitidine)
Figure 7: Guadecitabine for MDS (October 14, 2020): Phase III - ASTRAL-3
Figure 8: Estybon (Intravenous) for MDS (August 24, 2020): Phase III - INSPIRE (HR-MDS)
Figure 9: Onureg for MDS (June 12, 2020): Phase III - 003 (Low-Risk)
Figure 10: Pevonedistat for MDS (May 29, 2020): Phase II - w/Azacitidine
Figure 11: Inqovi for MDS (December 9, 2019): Phase III - ASCERTAIN (vs. Decitabine)
Figure 12: Magrolimab for MDS (December 9, 2019): Phase Ib - w/Azacitidine (AML/MDS)
Figure 13: Vidaza for MDS (December 9, 2019): Phase II - w/Durvalumab
Figure 14: Key upcoming events in MDS
Figure 15: Probability of success in the hematologic pipeline
Figure 16: Clinical trials in MDS
Figure 17: Top 10 drugs for clinical trials in MDS
Figure 18: Top 10 companies for clinical trials in MDS
Figure 19: Trial locations in MDS
Figure 20: MDS trials status
Figure 21: MDS trials sponsors, by phase

Table 1: Incident cases of MDS, 2019–28
Table 2: Marketed drugs for MDS
Table 3: Pipeline drugs for MDS in the US
Table 4: Eprenetapopt for MDS (December 28, 2020)
Table 5: Guadecitabine for MDS (October 14, 2020)
Table 6: Estybon (Intravenous) for MDS (August 24, 2020)
Table 7: Onureg for MDS (June 12, 2020)
Table 8: Pevonedistat for MDS (May 29, 2020)
Table 9: Eprenetapopt for MDS (December 9, 2019)
Table 10: Inqovi for MDS (December 9, 2019)
Table 11: Magrolimab for MDS (December 9, 2019)
Table 12: MBG453 for MDS (December 9, 2019)
Table 13: Venclexta for MDS (December 9, 2019)
Table 14: Vidaza for MDS (December 9, 2019)
Table 15: Historical global sales, by drug ($m), 2015–19
Table 16: Forecasted global sales, by drug ($m), 2021–25